Fadrozole
From Self-sufficiency
| File:Fadrozole.png | |
| Systematic (IUPAC) name | |
|---|---|
|
4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 102676-31-3 |
| ATC code | none |
| PubChem | CID 59693 |
| Chemical data | |
| Formula | C14H13N3 |
| Molar mass | 223.27 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Fadrozole (INN, marketed as Afema by Novartis) is an aromatase inhibitor[1] that has been introduced in Japan for the treatment of breast cancer.
It is selective.[2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />See also
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Pharmacology stubs
- 2Fix
- Aromatase inhibitors
- Imidazopyridines
- Nitriles
